MedPath

FDA Approves Lymphoseek for Head and Neck Cancer Lymphatic Mapping

• The FDA has approved Navidea Biopharmaceuticals' Lymphoseek for sentinel lymph node biopsy guidance in head and neck cancer patients with squamous cell carcinoma of the oral cavity. • Lymphoseek, a radioactive diagnostic imaging agent, was initially approved in 2013 for locating lymph nodes in breast cancer and melanoma patients. • This expanded indication marks the second approval for Lymphoseek in the U.S., broadening its clinical utility in cancer staging. • Navidea has a distribution partnership with Cardinal Health for Lymphoseek, which was first launched in the U.S. in May 2013.

The FDA has granted approval for Navidea Biopharmaceuticals' Lymphoseek injection for expanded use in guiding sentinel lymph node (SLN) biopsy for patients with head and neck cancer, specifically squamous cell carcinoma of the oral cavity. This marks the second indication for Lymphoseek in the United States, potentially improving staging and surgical planning for these patients.
Lymphoseek, a radioactive diagnostic imaging agent, was initially approved by the FDA in March 2013 for identifying lymph nodes in patients with breast cancer or melanoma undergoing sentinel lymph node biopsy. The agent is designed to be injected and then tracked using imaging to locate the sentinel lymph nodes, which are the first nodes to which cancer cells are likely to spread.

Commercialization and Distribution

Lymphoseek was launched in the U.S. in May 2013, with Navidea partnering with Cardinal Health for its sale and distribution. Navidea began reporting revenue from Lymphoseek in the second quarter of 2013. In Q2 2013, Navidea's share of product revenue from Lymphoseek sales was $128,000, followed by $144,000 in Q3 2013, $343,000 in Q4 2013, and $627,000 in Q1 2014.

Additional Regulatory Filings

Navidea had an additional Supplemental New Drug Application under review by the FDA, seeking approval for more flexible and extended utilization practices of Lymphoseek, with a decision date set for October 16, 2014.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Citius Pharmaceuticals' Lymphir for CTCL Treatment

The FDA has approved Citius Pharmaceuticals' Lymphir, a reformulated version of a previously withdrawn lymphoma therapy, for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL). This marks a significant advancement for patients with this rare form of non-Hodgkin lymphoma, offering a new treatment option with the potential to rapidly reduce skin disease and control symptomatic itching without cumulative toxicity.

FDA Approves Subcutaneous Opdivo Qvantig for Multiple Solid Tumors

The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for subcutaneous use, offering a new administration option for various solid tumors.
The approval was based on the CheckMate-67T trial, demonstrating non-inferior pharmacokinetic exposures and comparable safety to intravenous Opdivo.

FDA Approves Enhanced Head Electrode Arrays for Novocure's Optune Gio in Glioblastoma Treatment

The FDA has cleared Novocure's new head flexible electrode (HFE) transducer arrays for Optune Gio, a wearable device used in treating glioblastoma.
The modified HFEs are designed to enhance patient comfort during treatment with Optune Gio, which delivers Tumor Treating Fields (TTFields).

Novocure's Optune Gio Receives FDA Approval for Enhanced Head Electrode Design in Glioblastoma Treatment

Novocure's Optune Gio, a wearable device for glioblastoma treatment, has received FDA approval for its new head flexible electrode (HFE) transducer arrays.
The updated HFEs are designed to enhance patient comfort during treatment with Optune Gio, which delivers tumor-treating fields (TTFields) to inhibit cancer cell growth.

FDA Accepts Bayer's Nubeqa sNDA for Metastatic Hormone-Sensitive Prostate Cancer

The FDA has accepted Bayer's sNDA for Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT) for mHSPC.
The sNDA is based on positive Phase III ARANOTE trial results, demonstrating improved radiological progression-free survival (rPFS).

NovoCure's Wearable Device Receives FDA Approval for Metastatic Cancer Treatment

NovoCure's wearable device, utilizing Tumor Treating Fields (TTFields) technology, has gained FDA approval for treating metastatic cancer.
The non-invasive device employs electric fields to target and slow the growth of cancer cells, presenting a novel option for patients with limited alternatives.

FDA Accepts Telix Pharmaceuticals' Pixclara for Priority Review in Glioma Diagnosis

The FDA has accepted Telix Pharmaceuticals' New Drug Application for Pixclara, a diagnostic agent for gliomas, granting it priority review.
Pixclara aims to improve glioma diagnosis by overcoming limitations of conventional MRI, offering quicker and more reliable results.

FDA Grants Priority Review to Telix's Pixclara for Glioma Imaging

The FDA has accepted Telix Pharmaceuticals' New Drug Application for TLX101-CDx (Pixclara), a PET imaging agent for glioma, granting priority review.
Pixclara targets LAT1 and LAT2, offering potential as a companion diagnostic for Telix's TLX101-Tx, currently in development for glioblastoma.

FDA Approves Biotronik's Left Bundle Branch Area Pacing System

The FDA has granted approval for Biotronik's Selectra 3D catheter and Solia S lead system for left bundle branch area pacing (LBBAP).
The approval was based on the BIO-CONDUCT trial, which demonstrated a 95.7% implant success rate and a low 1.7% lead-related complication rate.

FDA Approves Lymphir (denileukin diftitox-cxdl) for Relapsed/Refractory Cutaneous T-Cell Lymphoma

The FDA has approved Lymphir (denileukin diftitox-cxdl) for treating relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
Lymphir is a novel immunotherapy targeting the interleukin-2 (IL-2) receptor on malignant T-cells and Tregs, offering a new treatment option for CTCL patients.

Reference News

[1]
FDA Approves New Indication For Navidea's Lymphatic Mapping Agent - RTTNews
rttnews.com · Oct 12, 2024

Navidea Biopharmaceuticals' Lymphoseek gains FDA approval for expanded use in head and neck cancer patients, marking its...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy